Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Plasma cell 467Lymphoid 356Other hematologic neoplasm 160Myeloid 28Genitourinary 19Dermatologic 19Gastrointestinal 15CNS 12Classical hematology 9Sarcoma 8Tumor-Agnostic 6Thoracic 6Gynecologic 6Other solid neoplasm 5Head & Neck 5Endocrine 2Breast 2NET 1

Conditions

Neoplasms 5Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Lenalidomide × Tumor-Agnostic × Clear all
NCT06251648 2024-02-09

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

University Hospital, Caen

Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT03113695 2022-07-05

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

University of California, San Diego

Phase 1 Completed
4 enrolled
Tumor-Agnostic

Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00046735 2019-11-18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Celgene

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT01750983 2019-02-25

Ipilimumab and Lenalidomide in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
101 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡